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Legionellosis is not a common diagnosis in HIV- 
infected patients, despite its frequency among other 
groups of immunocompromised patients, particularly 
those with impaired cell-mediated immunity [1,2]. As 
the diagnosis of Legionella pneumophila infection relies 
on specific microbiological tests, its frequency could be 
underestimated if it is not systematically evoked in 
severe pulmonary disorders in AIDS patients [2]. Few 
studies have been published on the association of HIV 
and L. pneumophila infections [2]. According to these 
reports, a good response can be obtained with standard 
treatment for L. pneumophila pneumonia. We report a 
culture-proven case of L. pneumophila pneumonia in an 
HIV-infected patient in whom respiratory specimens 
remained culture positive after 18 days of combination 
therapy with two antimicrobial agens with very low 
MICs for the strain involved. The patient eventually 
recovered after prolongation of the same treatment for 
a period greatly exceeding that usually recommended 
A 51-year-old woman was admitted with fever, 
cough and shortness of breath. Her past medical history 
included an intolerance to erythromycin, and HIV-1 
seropositivity. Two months before admission, her CD4 
cell count was 300/mm3. At admission, her body 
temperature was 3 9 T .  Auscultation of the lungs 
revealed diminished breath sounds, and diffuse crepi- 
tations. The chest radiograph disclosed a diffuse inter- 
stitial infiltrate. The pO2 was 78 mmHg on room air. 
The CD4 cell count was 50/mm3, and the plasma HIV- 
1 R N A  titer was 5.6 loglo/mL. Parasitologic studies 
of the bronchoalveolar lavage (BAL) fluid disclosed 
Pneumocystis carinii cysts and trophozoites. Direct 
fluorescent antibody (DFA) staining for L. pneumophila 
(Monofluo, Diagnostics Pasteur, France) disclosed many 
fluorescent rods, and culture on buffered charcoal 
yeast extract (BCYE) agar confirmed the presence of 
L. pneumophila, serogroup 1, sensitive both to macrolides 
(erythromycin MIC = 0.75 mg/L) and to fluoroquino- 
lones (pefloxacin MIC=1 mg/L). Oral treatment was 
started with pefloxacin 400 mg twice a day, spiramycin 
2 Xl0' IU three times a day, sulfamethoxazole 1600 mg 
three times a day and trimethoprim 320 mg three 
times a day. Her clinical status improved, spiramycin 
and pefloxacin were discontinued 18 days later, and 
trimethoprim-sulfamethoxazole was continued at a 
prophylactic dose. 
PI. 
She gradually deteriorated, with high-grade fever 
and relapse of the initial respiratory symptoms. Auscul- 
tation of the lungs revealed diffuse crepitations. A new 
BAL, 7 days after the discontinuation of pefloxacin and 
spiramycin, disclosed no l? carinii, but DFA staining for 
Legionella showed a few fluorescent rods. Culture on 
BCYE agar confirmed the presence of L. pneumophila, 
serogroup 1, with an antibiotic sensitivity pattern 
similar to that of the first isolate. Electrophoretic profiles 
of the two isolates, after arbitrarily primed P C R  (AP- 
PCR), were similar. A second course of oral spiramycin 
and pefloxacin at  the same dose as used previously was 
given for 1 month, with the symptoms finally resolving. 
Antiretroviral treatment consisting of indinavir 800 mg 
three times a day and stavudine 30 mg twice a day was 
introduced. After 20 months of follow-up, the patient 
has not relapsed. The CD4 cell count is 350/mm3, and 
the plasma HIV-1 R N A  titer is 4.4 l o g d m l .  Serologic 
tests for Legionella remained negative (<1/16). No 
Legionella species were detected in the water supplies of 
our department, despite regular cultures on BCYE. 
Four series have been published on the association 
of HIV and L. pneumophila, totaling 28 cases. In these 
studies, the diagnosis of L. pneumophila pneumonia 
in HIV-infected patients was mostly based on DFA 
staining, and cultures on BCYE agar were almost always 
negative. Serologic tests were significantly positive in 
two of the four patients tested in one series, despite 
their severe immunodeficiency [2]. The fact that 
cultures on appropriate media are almost always 
negative is puzzling. One explanation could be that 
HIV-infected patients are frequently undergoing anti- 
biotic treatment when the diagnostic procedures are 
performed. Trimethoprim-sulfamethoxazole has some 
activity against L. pneumophila, according to in vitro and 
animal studies [3,4], as well as clinical studies [5]. HIV- 
infected patients are often on trimethoprim-sulfa- 
methoxazole prophylaxis when their CD4 cell counts 
are less than 200/mm3. This could partly explain 
both culture negativity and the low frequency of 
L. pneurnoplzila infection in this population. Recently, 
99 cases of culture-proven legionnaires' disease were 
reviewed in the Paris area between January 1989 and 
June 1996 [6]. Eleven cases occurred in HIV-infected 
patients, whose main characteristics were predominance 
of serogroup 1 (nine cases), isolation from respiratory 
secretions alone in every case, late occurrence during 
HIV infection (eight patients had AIDS), and a high 
mortality rate (five deaths). At least three of the 11 cases 
were hospital-acquired. 
The treatment of legionellosis in immunocom- 
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promised HIV-infected patients should not dffer from 
the usual recommendations [l], according to Blatt et al. 
In their series, four of eight patients were cured with 
erythromycin alone, one with ciprofloxacin alone, one 
with sulfamethoxazole-trimethoprim, and two with 
the combination of doxycycline and rifampin. None 
died of legionellosis. Only one patient relapsed, 6 
months after the first episode, but he responded well to 
a second treatment and did not relapse during 24 
months of follow-up [2]. 
The persistent negativity of indirect fluorescent 
antibody assay (3 months of follow-up) is not surprising, 
as it was the case in half the patients tested in one series 
[2]. The association of L. pneumophila and I? cariizii is 
not unusual in HIV-infected patients: according to the 
literature, L. pneumophila is frequently associated with 
other opportunistic pathogens in HIV-infected patients, 
mostly I? carinii (four among the eight cases reported by 
Blatt et a1 [2] ,  but they also had two cases associated 
with Rlzodococrur eqmi). More unusual is the poor 
therapeutic response: despite early and prolonged 
treatment with two antimicrobials both active on the 
isolate in vitro, the symptoms returned a few days after 
discontinuation of the intensive treatment phase, and 
the respiratory samples were again culture positive 1 
week later. We assumed that it was not a case of 
reinfection, for the following reasons: (1) the serogroup 
and electrophoretic profile after AP-PCR of the second 
Legionella isolate were the same as those of the first; 
(2) the patient was still hospitalized when symptoms 
returned, and the mode of acquisition was probably not 
nosoconllal, as Legionella could not be isolated from our 
hospital water system. 
Treatment failure in this case could be attributed 
to oral administration. However, there was no potential 
cause of digestive malabsorption, and the doses of 
pefloxacin (800 mg/day) and spiramycin (6x1O6 IU/ 
day) were largely adequate for the patient’s body 
weight. Combinations including pefloxacin were the 
most active in a retrospective study of 60 cases of 
legionnaires’ disease [7] ,  even though a case of treat- 
ment failure with a fluoroquinolone (ofloxacin, per 0s)  
was reported, in which the combination of erythro- 
mycin and rifampin was eventually successful [8] .  The 
association of Legionella with another pathogen was not 
identified as a bad prognosis factor and did not modify 
therapeutic response in the series of Blatt et al [ 2 ] .  We 
used spiramycin instead of erythromycin because of our 
patient’s intolerance of erythromycin, but the activity 
of these two compounds on Legionella is equivalent, 
according to experimental (guinea pig model of peri- 
tonitis [91, and pneumonia models [lo]) and clinical 
studies [11,12]. Moreover, the second treatment course 
with the same compounds at  the same doses and by the 
same route was effective, indicating that this treatment 
was well adapted but had to be given for longer. It is 
noteworthy that despite the persistence of live L. 
pnetrrnophila in the lungs for at least 4 weeks, our patient 
recovered and has not relapsed (20-month follow-up). 
In conclusion, L. pnetttnophila pneumonia in HIV- 
infected patients may linger in patients treated with 
oral antimicrobial agents, despite in vitro activity; oral 
therapy, even with agents such as macrolides and 
fluoroquinolones that are well absorbed from the gastro- 
intestinal tract, may be ineffective unless therapy is 
prolonged beyond the usual duration of 14-21 days. 
Pierre Tatteviiz ‘, Patrick Miailhes ’, Christine Lawrence‘, 
Stkphanie Franchi-Abella I ,  
Jean~acques Moizstrez’, Premavatliy Rajappalan- 
L.evasseirr4 and Daniel Vittecoq I *  
‘UMIT, HGpital Paul Brousse, 94800 Villejuif, 
France; ’Service de Microbiologie, 
H6pital Raymond Poincari., Garches; ‘Service de 
Mkdecine Interne, HGpital Paul Brousse, 
Villejuif, and ‘Institut National de la Santk et de la 
Recherche Mkdicale U 13, Paris, France 
*Tel: 1331 45 59 38 70 Fax: 1331 45 59 36 16 
E-mai l :  daniel.vittecoq@pbr.ep-hop-paris.fr 
References 
1. Yu VL. Legionella pnerimophila (legionnaires disease). In Mandell 
GL, Douglas R G  Jr, Bennett JE, eds. Principles and practice of 
infectious diseases, 4th edn. New York: Churchill Livingstone. 
1995: 2087-97. 
2. Blatt SP, Ilolan MJ, Hendrix CW, Melchrr JP  Legionnairer 
disease in human immunodeficiency virus-infected patients: 
eight cases and review. Clin Infect Dis 1994; 18: 227-32. 
3. Saravolatz LD, Pohlod DJ, Quinn EL. In vitro susceptibility of 
Lqqionella prreumophifa, serogroups 1-IV J Infect DIS 1979; 140. 
251. 
4. Plouffe JF, Para MF, Bollin GE. Sulfarnethoxazole-trinirthopriin 
treatment of guinea pigs infected with Lcgionella pnerrmophrla. 
J Infect Dis 1984; 150: 78&2. 
5. Le Saux NM, Sekla L, McLeod J, et al. Epidemic of nosocomial 
legionnaires’ disease in renal transplant recipients: a case-control 
and environmental study. Can Med Assoc J 1989; 140: 
6. Nauciel C, Matsiota-Bernard P. Ronco E, Lawrence C .  
Legionellosis and human immunodeficiency infection [abstract 
1811. In: 16th RICAI, Paris, December 1996: 12. 
7. Dournon E, Mayaud Ch, Wolff M, et al. Comparison of the 
activity of 3 antibiotic regimens in severe Legionnaires’ disease. 
J Antimicrob Chemother 1990; 26(suppl B): 129-39. 
8. Salord JM, Matsiota-Bernard P, Staikowsky E Kirstrtter M, 
Frottier J, Nauciel C. Unsuccessful treatment of Le.qioriella 
pneumophila infection with a fluoroquinolone. Clin Infect Dis 
1993; 17: 518-19. 
9. Dournon E, Rajagopolan P. Comparison of spiramycin and 
erythromycin in the treatment of experimental guinea pig 
legionellosts. J Antimicrob Chemother 1988; 22(supp1 H): 
69-72, 
1047-53. 
C o r r e s p o n d e n c e  667 
10. Nowicki M, Paucod JC, Bornstein N, Isoard P, Fleurette J. 
Efficacy of spiramycin on experimental airbone legionellosis in 
guinea pigs. J Antimicrob Chemother 1988; 22(suppl B): 63-8. 
1 1 .  Mayaud C, Dournon E, Montagne V, Denis M, Rossert J, 
Akoun G. Etticacy of intravenous spiramycin in the treatment of 
severe Legionnaires' disease. J Antitnicrob Chemother 1988; 
2 2 ( ~ ~ p p l  B): 179-82. 
12. Edelstein PH. Antimicrobial chemotherapy for legionnaires' 
disease: a review. Clin Infect Dis 1995; 2l(suppl 3): S265-76. 
Escherichia coli 0157 infection masquerading as 'rectal 
bleeding': a further problem for infection control 
Clin Microbiol Infect 1998; 4: 667 
Infection with Escherichia coli 0 1 5 7  can result in a range 
of symptoms, from mild diarrhea to severe hemor- 
rhagic colitis [l]. The appearance of stools from 
patients with severe E. coli 0 1 5 7  colitis has been 
described as 'all blood and no stool' [2], which can be 
mistaken for non-infectious rectal bleeding. 
We have recently seen two separate incidents 
where patients were admitted to our hospitals with a 
diagnosis of rectal bleeding and infection was not 
suspected. Subsequent stool cultures yielded E. coli 
0157  and isolation procedures, as per policy, were 
introduced only after the diagnostic delay. Further 
enquiry elicited a history of preceding diarrhea in both 
cases. In one episode, indistinguishable isolates of E. coli 
were subsequently obtained from two further patients 
and three members of the nursing staff on the same 
hospital ward, indicating cross-infection during the 
window period before isolation was instituted. 
We are aware of other serious incidents of hospital 
cross-infection occurring with this organism [3]. As 
E. coli 0157  has a particularly low infectious dose [I], 
nosocomial transmission can occur when infection 
control procedures are suboptimal [4]. This is more 
likely when staffing levels are inadequate, and patients 
are moved around quickly from ward to ward after 
admission, as happened in our second case. 
We suggest that specific enquiry for a preceding 
history of diarrhea should be made in all cases of rectal 
bleeding, as this may be due to E. coli 0157. if such a 
history is forthcoming, infection precautions should be 
taken from the start. 
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lack of efficacy of ozone therapy in HIV infection 
Clin Microbiol Infect 1998; 4: 667-669 
It has been shown that ozone promptly inactivates 
HIV-1 in vitro [l]  and may alter surface markers in 
HIV-I-infected lymphocytes. However, owing either 
to poor methodology [2] or to multiple comple- 
mentary treatments, the usefulness of ozone therapy in 
vivo remains questionable [3]. The advantages and 
disadvantages of ozone therapy in HIV-1 infection have 
been discussed (41, particularly with regard to the 
potential risk of enhancing HIV-1 replication because 
of the release of tumor necrosis factor-a and/or the 
transient oxidative stress. O n  July 1995, we decided to 
investigate whether a well-standardized method of 
ozonated autohemotherapy (OyAHT) [5] could affect 
immunologic and virologic markers of the course of 
HIV-1 infection in drug-naive patients. This decision 
was taken because: first, some patients refused anti- 
retroviral therapy; second, there was a considerable 
interest in using ozone therapy in HIV infection; and 
third, it could not be foreseen that the actual triple 
antiretroviral regimen would be so effective. The study 
population was limited initially to 10 HIV-1- and 
hepatitis C virus-positive adults enrolled in 1995-96, 
who signed an informed consent to be treated by ozone 
therapy. The treatment consisted of collecting 300 g 
of blood from each patient in a Baxter bag for 
autotransfusion (mod. R0530) and exposing it to 
300 mL of 95% 02/5% 0 3  at an 0 3  concentration of 
67 mg/L (20.1 mg 0 3  per treatment). Because of 
a low prothrombin time (PT), citrate-phosphate- 
dextrose-adenine (CPDA) was used as the anti- 
coagulant for blood from patient 3263. Blood samples 
from all of the other patients were treated with heparin 
calcium salt (30 U/g blood) after CPDA had been 
eliminated from the bag. Blood was mixed thoroughly 
with the gas, avoiding foaming for at least 5 min until 
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pO2 reached a plateau at about 400 mmHg and ozone 
had fully reacted with blood. immediate retransfusion 
